Bill Details
View committees (2)
View cosponsors (2)
AI Summary This summary was generated by AI from the bill text. AI can get information wrong.
This bill would expand Medicare coverage for some people who receive intravenous immune globulin, or IVIG, at home. Right now, Medicare covers home IVIG administration for people with primary immune deficiency diseases. This bill would add coverage for two more nerve-related conditions, starting January 1, 2027: chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. It would also let Medicare set different payment amounts depending on the condition being treated.
- Medicare home coverage for IVIG would be expanded beyond primary immune deficiency diseases.
- Starting January 1, 2027, people with chronic inflammatory demyelinating polyneuropathy could qualify for this home treatment coverage.
- Starting January 1, 2027, people with multifocal motor neuropathy could also qualify for this home treatment coverage.
- The Secretary of Health and Human Services could set different payment rates for home IVIG depending on the condition being treated, using the normal rulemaking process.
Official Summaries
Medicare IVIG Access Enhancement Act of 2025
This bill provides for Medicare coverage of in-home administration of intravenous immune globulin to treat chronic inflammatory demyelinating polyneuropathy (CIDP) or multifocal motor neuropathy. (CIDP is an autoimmune condition that causes symptoms such as muscle weakness and numbness; multifocal motor neuropathy is a variant of CIDP that only causes asymmetric muscle weakness.)
Current Full Text
[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1143 Introduced in House (IH)]
<DOC>
119th CONGRESS
1st Session
H. R. 1143
To amend title XVIII of the Social Security Act to expand coverage of
the in-home administration of intravenous immune globulin under the
Medicare program.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
February 7, 2025
Mr. Smith of Nebraska (for himself and Mr. Garamendi) introduced the
following bill; which was referred to the Committee on Energy and
Commerce, and in addition to the Committee on Ways and Means, for a
period to be subsequently determined by the Speaker, in each case for
consideration of such provisions as fall within the jurisdiction of the
committee concerned
_______________________________________________________________________
A BILL
To amend title XVIII of the Social Security Act to expand coverage of
the in-home administration of intravenous immune globulin under the
Medicare program.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Medicare IVIG Access Enhancement Act
of 2025''.
SEC. 2. EXPANDING COVERAGE OF THE IN-HOME ADMINISTRATION OF INTRAVENOUS
IMMUNE GLOBULIN UNDER THE MEDICARE PROGRAM.
(a) In General.--Section 1861 of the Social Security Act (42 U.S.C.
1395x) is amended--
(1) in subsection (s)(2)(Z), by inserting ``(and, beginning
January 1, 2027, for the treatment of chronic inflammatory
demyelinating polyneuropathy and multifocal motor neuropathy)''
after ``primary immune deficiency diseases''; and
(2) in subsection (zz), by inserting ``(or, beginning
January 1, 2027, with diagnosed chronic inflammatory
demyelinating polyneuropathy and multifocal motor neuropathy)''
after ``primary immune deficiency disease''.
(b) Authority for Variance in Payments.--Section 1842(o)(8) of the
Social Security Act (42 U.S.C. 1395u(o)(8)) is amended by inserting
``and may vary depending on whether such administration is related to
treatment of a primary immune deficiency disease or the treatment of
chronic inflammatory demyelinating polyneuropathy or multifocal motor
neuropathy (as determined appropriate by the Secretary through notice
and comment rulemaking)'' after ``of 2012''.
<all>